Genomic Epidemiology of *Enterococcus faecium* Bloodstream Infections During a VanB-

type VRE Peak Reveals an Oligoclonal Scenario: An Observational Study at a German

University Hospital (2017–2022)

Leonard Knegendorf [1,2], Anna Sommer [3,4], Claas Baier [1,5], Robert E. Weber [3,4], Martin A.

Fischer [3,4], Guido Werner [3,4], Stefan Ziesing [1], Dirk Schlüter [1,6]

1 Hannover Medical School (MHH), Institute for Medical Microbiology and Hospital Epidemiology, Hannover, Germany

2 TWINCORE Centre for Experimental and Clinical Infection Research, Institute for Molecular Bacteriology, Hannover,
Germany

3 Robert Koch Institute, Department of Infectious Diseases, Wernigerode Branch, Wernigerode, Germany

4 National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany

5 Infection Prevention and Control Department, Agaplesion Diakonieklinikum Rotenburg, Rotenburg (Wümme), Germany

6 Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany

Leonard Knegendorf and Anna Sommer contributed equally as first authors. The order of names is
alphabetical.

Address correspondence to Leonard Knegendorf, Knegendorf.Leonard@mh-hannover.de

Running Title: Oligoclonal *vanB*-type VRE in Bloodstream Infections

Keywords: Enterococcus faecium, vancomycin resistance, bloodstream infection, genomic
epidemiology, split k-mer analysis

Conflict of interest: The authors declare no conflict of interest.

Abstract

Background: A substantial and rapid increase, followed by a sharp decline in *vanB*-type vancomycin-resistant *E. faecium* (VRE), occurred in Germany in the late 2010s. This unusual epidemiological trend prompted detailed genomic investigations to explore the underlying dynamics at a German university hospital.

Methods: We retrospectively analyzed 344 *E. faecium* bloodstream infection (BSI) isolates collected between 2017 and 2022. Isolates were classified as *vanA*-positive, *vanB*-positive, or *van*-negative, while VRE was defined as *vanA*- or *vanB*-positive. Molecular typing included multilocus sequence typing (MLST), core genome MLST (cgMLST), and split k-mer analysis (SKA). Clonal relationships and potential patient-to-patient transmission events were assessed by integrating genomic data with machine-aided analysis of available longitudinal patient movement data.

Results: High-resolution genomic analysis of BSI isolates revealed an oligoclonal scenario involving multiple epidemic lineages (e.g., sequence type (ST)117/complex type (CT)71, ST117/CT929, ST117/CT2505, ST80, and ST262) with distinct *van* genotypes and dynamic changes over time. Overall, genomic overlap between *vanA*-positive, *vanB*-positive, and *van*-negative populations was minimal. The *vanB* surge, peaking in late 2018-early 2019, was mainly driven by ST117/CT71, ST117/CT36, and ST117/CT1917. SKA provided enhanced discriminatory power over cgMLST. The inferred transmission events linked bloodstream infections separated by long intervals (median, 106 days).

Conclusions: Accurate characterization of the transient *vanB*-type VRE peak required an integrated genomic approach combining cgMLST, high-resolution SKA, and epidemiological data. These comprehensive methods enable infection prevention and control (IPC) teams to distinguish true outbreaks from apparent epidemiologic clusters of polyclonal isolates. This allows for accurate interpretation and precisely targeted interventions where evidence supports transmission.

Word count abstract: 250

Importance

Vancomycin-resistant *Enterococcus faecium* is an increasingly important nosocomial pathogen worldwide. Understanding its epidemiology and transmission dynamics is critical to effectively control its spread. This study documents shifting *E. faecium* populations within a high-risk hospital environment, including both vancomycin-resistant and vancomycin-susceptible bloodstream isolates. Virulence gene profiling demonstrated that hospital-associated variants predominated across all major lineages, independent of vancomycin resistance, indicating that hospital adaptation is a common feature of both resistant and susceptible populations. Detailed genomic analyses, combining core genome multilocus sequence typing with high-resolution split k-mer analysis, integrated with comprehensive epidemiological tracking, were critical to accurately depict complex epidemiological dynamics. This combined approach allows precise differentiation between monoclonal outbreaks and oligoclonal transmission, enabling more targeted infection prevention and control strategies.

Introduction

Enterococci are commensals of the human intestinal microbiome. Under certain conditions, however, they can also cause infections, particularly in immunocompromised and critically ill patients. They are a significant cause of nosocomial bloodstream infections. Of the many known *Enterococcus* species, only two are of major medical significance: *Enterococcus faecium* and *E. faecalis*. In particular, *E. faecium* isolates are characterized by high environmental resistance, an enhanced tolerance to disinfectants, and a wide range of acquired antibiotic resistances (1, 2). Hospital-associated isolates of this species differ from those colonizing the intestines of humans and animals. Genome comparisons show that infectious isolates fall into three distinct genomic clades called A1, A2, and B (3), whereas human commensal isolates of clade B are suggested to be reassigned to another species called *E. lactis* (4, 5).

Vancomycin is a first-line agent for the treatment of infections caused by enterococci, particularly *E. faecium*. Acquired resistance to vancomycin primarily occurs in members of the species *E. faecium* and to a much lesser extent in *E. faecalis*. Of the eight different variants of acquired vancomycin resistance, the *vanA* and *vanB* variants are of major medical importance. The *vanA* gene cluster is predominantly localized on plasmids that can be transferred between different strains. In contrast, the *vanB* gene cluster is mainly part of the bacterial chromosome, but can also be conjugated between different strains (6, 7). Both types of acquired vancomycin resistance could be transferred by clonal expansion or horizontal transfer.

Both national and international surveillance programs and schemes report comparably high rates
of VRE in Germany. While VRE-BSI showed a rapid increase up until 2020, more recent data
indicate a subsequent decline in case numbers (8). Data from the National Reference Centre for
Enterococci, along with various publications on patient-associated enterococci, confirm the
predominant prevalence of *vanB*-type VRE in Germany during the increase in VRE-BSI up to 2020.

The incidence of VRE BSI in Germany is relatively low, but it doubled from 1.7 to a peak of 3.0 per
100,000 in 2021 before declining back to 1.7 in 2023 (8). It ranges from 0.1% to 10.6% in high-risk
hospitalized patients (9). Whole-genome sequencing (WGS) enables detailed strain classification,
with MLST assigning a sequence type (ST) from allelic profiles of seven housekeeping genes and
cgMLST assigning a complex type (CT) from the unique combination of alleles across 1,423
conserved loci (10).

Genomic analyses of local and regional invasive VRE strains in Germany from 2010 to 2020
revealed the preferential spread of certain strain variants associated with *vanB*-type resistance. For
instance, *E. faecium* isolates of ST117/CT71/*vanB* were found to be widespread throughout
Germany, whereas isolates of ST80/CT1065/*vanB* predominantly spread regionally focusing on
southern and western Germany (11). Local outbreaks may be dominated by unique strain types
such as ST80/CT1013/*vanB* as recently described (12).

The objective of this study was to investigate the clonal structure and temporal dynamics of
bloodstream-associated *E. faecium* during a transient VanB-type VRE peak. To this end, we
retrospectively analyzed isolates from BSIs in patients treated at Hannover Medical School, a
1,500-bed tertiary university hospital in northern Germany that specializes, among other areas, in
solid-organ transplantation. The isolates were collected from 2017 to 2022 to cover the observed
increase and decrease of VRE prevalence in Germany as well as the impact of the SARS-CoV-2
pandemic. Isolates underwent WGS and molecular typing, followed by epidemiological tracking of
phylogenetically related strains to gain a deeper understanding of *E. faecium* epidemiology.

Materials and Methods

Clinical Case Definition

From October 11, 2017, to February 10, 2022, we included every *E. faecium* isolate from blood
cultures for which antimicrobial susceptibility testing was performed in routine diagnostics. We
included at least one strain per patient as well as strains with distinct colony morphology or isolated
more than seven days after the initial isolate. We performed retrospective identification of isolates
by querying the laboratory information system database (M/Lab, DORNER Health IT Solutions,
Müllheim, Germany) and manually reviewing available isolates in our strain collections, which the

laboratory routinely maintains. The isolates originated from various hospital wards, including the
pediatric clinics, thus ensuring a comprehensive representation across different clinical settings.
Throughout the study period, all patients who tested positive for VRE were isolated in single rooms
or cohorted, and staff wore personal protective equipment (gowns and gloves).

Ethics committee of Hannover Medical School gave ethical approval for this work (No.
10388_BO_K_2022). Since this was a retrospective quality-assuring study, Ethics Committee and
Data Protection Commissioner of Hannover Medical School waived the need for informed consent.

Bacterial Isolates and Susceptibility Testing

Blood samples were inoculated in BD BACTEC™ Plus Aerobic and BD BACTEC™ Lytic
Anaerobic culture vials (BD, Heidelberg, Germany) and incubated in a BD BACTEC™ FX system
according to the manufacturer's instructions. When flagged positive, blood culture samples were
subcultured on solid media following internal laboratory protocols. Species identification was
performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) with a Vitek MS system (bioMérieux, Marcy-l'Étoile, France). Antimicrobial
susceptibility testing (AST) was conducted with a Vitek 2 system (bioMérieux, Marcy-l'Étoile,
France). A VRE was identified when the isolate tested resistant to vancomycin according to the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints that were valid
for the respective year of the study. Furthermore, a VanA phenotype was characterized by
resistance to vancomycin and teicoplanin, while a VanB phenotype was characterized by
resistance to vancomycin, and susceptibility to teicoplanin. Bacterial strains were stored in tryptone
soy broth (Oxoid, Wesel, Germany) supplemented with 30% glycerine (CHEMSOLUTE©, Th.
Geyer, Renningen, Germany) and kept at -80°C until whole-genome sequencing.

Whole-genome Sequencing, Quality Control and Genome Reconstruction

Bacterial cultures were grown in Brain Heart Infusion (BHI) broth. Genomic DNA was extracted
from an overnight culture using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). DNA
concentration was quantified with the Qubit dsDNA HS Assay Kit on a Qubit 4 Fluorometer
(Thermo Fisher Scientific, Karlsruhe, Germany). Sequencing libraries were prepared using the
Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA, United States), and paired-end
sequencing was conducted on a NextSeq instrument with a read length of 150 bp (Illumina, San
Diego, CA, United States). Raw sequence data quality was assessed using FQStat v0.0.12 (13),
FastQC v0.12.1 (Andrews *et al.*, https://www.bioinformatics.babraham.ac.uk/projects/fastqc/),
AQUAMIS v1.3.12 (14) and SeqSphere[+] v9.0.10 (Ridom, Münster, Germany). Eleven of 344
isolates were excluded due to inadequate quality control parameters and were not included in
further analyses. These included six with AQUAMIS failure, one with <95% good cgMLST targets,

and four due to multiple reasons including AQUAMIS failure. After quality control, Illumina raw
reads were *de novo* assembled using SPAdes v3.14.1 with default parameters (15).

Resistance and Virulence Gene Identification

The identification of the glycopeptide resistance genes *vanA* and *vanB* was performed using *de*
novo assembled contigs with CLC Genomics Workbench v24.0.1 and the 'Find Resistance with
Nucleotide Database' tool utilizing the QMI-AR Nucleotide Database.
Virulence gene screening was performed using VirulenceFinder for *Enterococcus faecium* and
Enterococcus lactis (16) with BLAST-based identification at ≥90 % sequence identity and ≥60 %
gene coverage. Genes of interest included adhesion and biofilm-associated factors such as the cell
wall-anchored adhesin *ecbA* (17), the biofilm formation-associated proline-rich surface protein *prpA*
(18), pilus gene cluster 1 (PCG-1) (19), and the hyaluronidase *hylEfm* (20), as well as the
Toll/interleukin-1 receptor domain-containing immunomodulatory genes *tirE1* and *tirE2* (21). In
addition, the bacteriocin gene *T8* was detected using a BLAST-based approach with the reference
sequence GenBank accession no. DQ402539.1 and identical threshold criteria. Visualization of
gene presence and variant calls followed the same layout, and graphical approach as Rubin *et al.*
(22).

Molecular Typing

MLST and cgMLST were carried out using established typing schemes in Ridom SeqSphere+
v9.0.10 (10, 23). Based on cgMLST, a Minimum Spanning Tree (MST) was inferred using the
option 'pairwise ignoring missing values'. CgMLST clusters were then defined by a pairwise allelic
difference threshold of ≤15 alleles. In addition to cgMLST, split k-mer analysis (SKA, v1.0) was
performed (24). Briefly, Split kmer files (.skf) were generated directly from paired raw FASTQ reads
using *ska fastq* with default filtering parameters and a split k-mer size of 15. All files were
summarized using *ska summary* for quality control, assessing the number of split k-mers and GC
content to confirm expected genome representation, sequencing depth, and data integrity.
Individual split k-mer files were then merged into a combined dataset using *ska merge*. Pairwise
genomic distances between isolates were then calculated using *ska distance*, and clusters were
assigned based on a 7-SNP cutoff and a minimum split k-mer identity of 90%.

Epidemiological Analysis

For in-depth epidemiological analysis, we manually extracted data on patient movements from the
hospital information system. Only inpatient stays were considered, and the analysis was limited to
the ward level. An epidemiological link was defined as two patients having overnight stays on the
same ward within a rolling 30-day window, with both stays preceding detection of the secondary
patient's bloodstream isolate. Cases that did not meet this criterion were not considered
epidemiologically linked. To systematically identify such links, a machine-aided approach was
implemented using Python (v3.13.3) and pandas (v2.2.3). We programmatically queried patient

movement data to identify qualifying patient-to-patient contacts based on the defined criteria and
the sampling dates of the corresponding bloodstream isolates. Information about VRE colonization
was retrieved manually from the laboratory information system.

To aid the interpretation of potential transmission routes, we stratified clinical departments into
three specialty groups based on the organ systems predominantly treated: (i) hematopoietic
system, including hematology-oncology and hematopoietic stem cell transplantation units; (ii)
excretory system, encompassing gastroenterology, hepatology, nephrology, urology, visceral
surgery, and related fields; and (iii) respiratory and cardiovascular system, including pneumology,
cardiology, cardiac surgery, and associated specialties. These groupings were used to reflect likely
overlap in patient pathways and potential transmission reservoirs across functionally related wards.
Departments that did not clearly align with one of these three categories were assigned to an
"Other" group. In cases where patients were treated in interdisciplinary intensive care units,
stratification was based on the underlying disease rather than the unit type.

Statistical analysis was performed using GraphPad Prism v10.5.0 (GraphPad Software, Boston,
MA, United States).

Results

The Rise and Fall of VanB type VRE at Hannover Medical School

The prevalence of VRE in patients at Hannover Medical School was assessed from 2013 to
2024_1 (suffix _1/_2 = first/second half-year). Following a sharp increase beginning in 2017 and
peaking in 2019, the absolute number of patients with the VanB phenotype steadily declined,
reaching pre-2017 levels by 2022. This downward trend began well before the overall decline in
cases treated at the hospital, which was largely attributable to the COVID-19 pandemic. In
contrast, the number of VRE patients with the VanA phenotype has remained largely constant
throughout the period (Fig. 1).

Isolate Collection Strategy

To analyze the temporal dynamics and genotype of *E. faecium* strains causing invasive disease,
we only included *E. faecium* strains isolated from blood cultures between 2017 and 2022. Of 414
isolates (98 VRE, 316 vancomycin-susceptible (VSE)), 344 underwent whole-genome sequencing;
68 isolates were not stored due to process-related omissions in routine storage workflows.
Following quality control, 333 isolates (80.43%) were included in the final analysis (Fig. 2A). The
annual distribution of *E. faecium* isolates showed considerable variation, with the highest count
recorded in 2021 (2017: n=5, 2018: n=61, 2019: n=52, 2020: n=92, 2021: n=102, and 2022: n=21;
Fig. 2B). Among the isolates, 238 did not carry any *van* resistance genes, while 19 were positive

for *vanA* and 76 for *vanB*. Due to the presence of the corresponding resistance determinants, the
isolates were classified as VRE. For subsequent population analysis, duplicate isolates were
excluded (same patient, same CT).

Temporal shifts in clonal lineages and *van*-genotype prevalence

Population analysis based on MLST and cgMLST revealed temporal variations in the distribution of
specific STs/CTs over time, with certain lineages, such as ST117/CT71/*vanB* and
ST117/CT929/*van*-negative, persisting throughout the study period (Fig. 3A/B). From 2019 onward,
however, ST117/CT71/*vanB* declined yet remained detectable, whereas ST117/CT929/*van*-
negative and ST117/CT2505, *van*-negative and *vanA* variants, became increasingly prevalent in
the following years.

The proportion of isolates with *vanA, vanB*, and *van*-negative genotypes varied throughout the
study period. *Van*-negative isolates consistently accounted for the majority of analyzed isolates,
with an increasing trend until 2021 (Fig. 3C). In this cohort, *vanA*-positive BSI isolates first
appeared in 2019 and remained at low, fluctuating levels thereafter. After maintaining a stable
prevalence of 30-40%, *vanB*-positive *E. faecium* BSI isolates declined sharply from the second half
of 2019 (2019_2) onward to approximately 10% in subsequent years.

A detailed analysis of isolates for each *van*-genotype underscores the contribution of certain clonal
lineages – such as ST117/CT71, ST117/CT36, and ST117/CT1917 – to the prevalence of *vanB*-
positive isolates (Fig. 3D). These clonal types were particularly prevalent during the second half of
2018 (2018_2) and the first half of 2019 (2019_1; Fig. 1, Fig. 3B/3D). Among the *van*-negative
isolates, ST117/CT929 was the most dominant, followed by ST80 (17 CTs, chiefly CT467 and
CT1470) and ST117/CT2505. Notably, *vanA*-positive isolates were rare and primarily detected in
ST80/CT1470.

Prevalence of *van* genotypes and virulence genes across diverse cgMLST clusters

An MST was generated using cgMLST with a cluster threshold of ≤15 alleles difference. The total
of 333 isolates was grouped into 17 distinct clusters, while 50 isolates remained as singletons (i.e.,
isolates not grouped into a cluster; Fig. 4A). Four out of the 17 clusters were designated major
cgMLST clusters, which included the predominant clones ST117/CT929 and ST117/CT2505
(Cluster 1, n=111), ST117/CT71 (Cluster 2, n=47), ST80/CT467 (Cluster 3, n=23), and
ST80/CT1470 (Cluster 4, n=15). In line with the analysis of *van* genotypes (Fig. 4D), Cluster 1 is
primarily composed of *van*-negative *E. faecium* isolates, whereas Cluster 2 is largely associated

with *vanB*-carrying variants (Fig. 4B). Although *vanA* was found in various clusters, Cluster 4
displayed the highest proportion of *vanA*-positive isolates.

Virulence gene analysis revealed consistent detection of multiple virulence determinants across all
major clonal lineages (Fig. S1). Where allelic differentiation was possible, hospital-associated (HA)
variants predominated; only *prpA* showed a higher prevalence of community-associated (CA)
alleles. *E. lactis*-like variants of the PGC-1 were exclusive to ST117/CT36, while PGC-1 was
completely absent from ST117/CT71 and from ST117/CT1917 isolates collected in 2018. Separate
virulence profiles were observed for ST117/CT1917 isolates emerging from 2021, corresponding to
the two temporally distinct appearances of ST117/CT1917 during and after the *vanB* peak
(Fig.⬚3). The genes *tirE1* and *tirE2* were detected in ST117/CT929, ST117/CT2505, ST117/CT71,
ST117/CT2035, and in the isolates of ST117/CT1917 from 2021 onward. No isolate carried
hylEfm. The bacteriocin gene *T8* was detected in 92.3% of isolates (Table S1).

SKA provides higher resolution clustering than cgMLST

The assignment of individual isolates to specific clusters has important implications for the
definition of outbreaks, hospital epidemiology, and the respective measures to prevent
transmission of enterococci. Therefore, we tested different methods for defining clusters of *E.*
faecium isolates, specifically focusing on cgMLST and SKA (Fig. 5). The classification of *E.*
faecium isolates follows a stepwise refinement across the applied typing methods, progressively
increasing resolution from MLST to cgMLST and SKA (Fig. 5). Starting with MLST, isolates were
assigned to 16 STs, with ST117 (n=225), ST80 (n=66), and ST262 (n=16) being the most
prevalent. While MLST provides only a broad genetic classification, cgMLST enhances resolution
by reassigning the 16 identified STs into 70 CTs. Using a cluster threshold of ≤15 alleles, these 70
CT-defined groups were further consolidated into 20 possibly outbreak-related clusters and 44
singletons (see also Fig. 4). While cgMLST relies on 1,423 core genes, SKA, as a k-mer-based
approach, also incorporates the accessory genome and intergenic regions. Due to this broader
genomic inclusion, a considerable number of isolates classified within cgMLST outbreak clusters
were reassigned as singletons in the SKA analysis. Using SKA, 40 clusters and 144 singletons
were identified.

Longitudinal Analysis of *E. faecium* ST117/CT71 Transmission

Understanding the epidemiological dynamics of *E. faecium* transmission is crucial for identifying
potential outbreaks and improving infection control strategies. This analysis focuses on cgMLST
cluster 2 (ST117/CT71) as one key driver of the *vanB* peak, examining spatial and temporal
relationships to assess potential epidemiologic linkages.

A total of 52 ST117/CT71 isolates, one ST117/CT5101, and one ST117/CT7838 from 47 individual
patients constituted the cgMLST cluster 2 (7 patients had two clinical isolates) (Fig. 6A). The
majority of patients were treated in one of three organ system-based specialty groups (see
Materials and Methods): hematopoietic system, excretory system, or cardiovascular and
respiratory system (Fig. S2). Of the 47 patients, 24 (51.1%) had a documented intestinal VRE
colonization prior to or at the time of infection. The cluster includes infection isolates from 2017-
2022, with affected patients hospitalized across 36 wards.

SKA subdivided cgMLST cluster 2 into eight clusters and 31 singletons (Fig. 6A). Within all SKA
clusters, epidemiological links could be detected, and five of the eight SKA clusters showed strong
epidemiological linkage indicative of potential transmission (same ward within 30 days; cluster 11,
12, 14, 15, and 16; Fig. 6B). Five isolate pairs originated from the same patient (cluster 11, 12, 15,
17, and 18). We also analyzed available epidemiological data (Fig. S2) for potential links between
all isolates in cgMLST cluster 2. Notably, 33 of 47 patients (70.2%) had been admitted to more
than two different wards during the study. Our analysis identified 29 patients with epidemiological
links within this cluster, despite their isolates being classified as singletons in SKA. Several
patients were linked to others either as potential sources or recipients, with some having multiple
plausible links, resulting in 55 total links across both SKA-defined clusters and singletons. The
median time interval between BSIs across all links was 106 days (95% CI: 59.0-246.0). Notably,
links in SKA-defined clusters showed a significantly shorter median interval between BSIs of 22
days compared to 118.5 days for links of SKA singletons (p = 0.0499, two-tailed Mann-Whitney U
test).

Discussion

The global emergence and dissemination of VRE remain pressing public health challenges, with
notable epidemiological trends documented in Europe and worldwide. Germany experienced a
marked increase in VRE cases during the late 2010s (25, 26), primarily driven by the clonal
expansion of *vanB*-positive lineages, notably ST117/CT71 (27–29). Similar *vanA* to *vanB*
dominance shifts have been observed globally, though circulating clones frequently remain region-
specific (11, 30–32).

At Hannover Medical School, VanB-type VRE cases rose sharply between 2017 and 2019, peaked
in 2019, then declined significantly and stabilized by 2021. For this study, we performed genomic
population analysis on 80.43% of all *E. faecium* BSI isolates meeting the inclusion criteria during
the study period, thus providing a robust representation of the clinical population. We identified an
overall proportion of 23.67% vancomycin resistance, aligning with European reports (33, 34).

CgMLST analysis revealed that *vanB*-type rise and fall were predominantly associated with
ST117/CT71 (31.3% in 2018_2; 21.4% in 2019_1) but also other clonal lineages like ST117/CT36

(14.3% in 2019_1) and ST117/CT1917 (6.3% in 2018_2). This aligns with findings from the
National Reference Centre on Enterococci and others, which reported country-wide expansion of
ST117/CT71/*vanB* until 2019, followed by significant decline (28, 29, 35). Similarly, Danish
surveillance detected the emergence of ST117/CT36 starting in 2019, likely originating from
German hospitals (32). Mills *et al.* demonstrated that emergent VRE lineages (ST80, ST117,
ST1478) achieve competitive advantage through bacteriocin *T8* production, present in 70-96% of
emergent lineages but only 16% of others, thereby providing significant colonization advantages *in
vivo* (36). In our study, *T8* was detected in >90% of bloodstream isolates, confirming its
widespread presence across dominant clonal lineages.

A tendency toward increased virulence gene content was observed in later-emerging lineages,
such as ST117/CT2505 and ST117/CT2035. Comparison with Danish data published by Rubin *et
al.* (22) supports this observation: whereas our ST117/CT36 isolates (mainly from 2018_2–2020)
lacked *ecbA*, *hylEfm*, and PGC-1 and exhibited overall lower frequencies of adhesion- and
colonization-associated genes, Danish ST117/CT36 isolates emerging from 2021 onward
displayed a broader virulence gene repertoire. The immunomodulatory *tirE* genes, identified by
Rubin *et al.* as specific for the latest emerging lineage ST80/CT2406 in Denmark, were
consistently present in our latest emerging lineages ST117/CT2035 and ST117/CT1917 isolated
from 2021 onward. The transient dominance of specific clones contrasts with Australian data
showing stable virulome and resistome profiles of major clonal lineages over 15 years (37). In our
study, even vancomycin-susceptible bloodstream isolates predominantly carried hospital-
associated (HA) virulence alleles, indicating that key adaptation traits are not limited to VRE.
Collectively, these findings suggest transmission efficiency drives lineage success rather than
escalating virulence, consistent with the view that enterococcal virulence factors primarily serve
ecological rather than pathogenic roles (38). While VRE now matches methicillin-resistant
Staphylococcus aureus (MRSA) in disease burden, awareness remains disproportionately focused
on MRSA (39).

The *vanB* peak did not coincide with an overall increase in BSIs, suggesting a shift in the
underlying population structure – likely due to changes in colonizing strain prevalence – rather than
an acute outbreak scenario. From mid-2019 onwards, *van*-negative isolates, primarily
ST117/CT929 (33.7% in 2021) and ST117/CT2505 (19.8% in 2021), became increasingly
prevalent. These lineages have been identified throughout Germany and rose notably from 2020
onward (35), with a recent study finding clonal isolates of these lineages being vancomycin-
resistant (40). Although ST117/CT71/*vanB* isolates decreased significantly after 2019, they
persisted throughout the study period. This suggests that there were ongoing transmission chains
despite intensified infection control measures during the SARS-CoV-2 pandemic, which were
expected to limit nosocomial transmission in general (41). These transmissions may have
originated from environmental reservoirs, within or outside the hospital.

In contrast, *vanA*-type associated BSIs – absent during the peak of *vanB* – emerged from 2019 onward, mainly driven by *vanA*-type ST80 expansion. Recent reports demonstrate rapid national and cross-border dissemination of new *vanA*-positive lineages (32, 42, 43). Alongside the generally more stable prevalence of the VanA phenotype, these observations highlight the complexity of VRE resistance dynamics and underscore the importance of continued molecular surveillance.

Although horizontal transfer of vancomycin-resistance genes in *E. faecium* is possible (7), *van*-positive isolates rarely cluster with *van*-negative isolates, indicating limited transmission of corresponding resistance determinants between vancomycin-resistant and VSE BSI isolates, confirming data from a Danish study covering the years 2015-2019 (44). This is further in accordance with experimental evidence showing no vancomycin resistance transfer *via* membrane vesicles (45) and genomic analyses confirming lineage-specific *vanA*-plasmids (46). Although acquisition of *van* elements to generate novel VRE types might not be a very frequent event, our data showed that it happened occasionally. From an evolutionary perspective, such events, even if they are very rare, may lead to a fast clonal expansion of certain novel strain types that appear by chance, i.e., a "bottleneck effect." In this context, extending genomic surveillance to include susceptible progenitor populations–such as VSE isolates from bloodstream infections, as in our case–has a clear and well-founded rationale. One example is ST117/CT2035, a van-negative lineage with consistent detection of multiple virulence gene variants typically found in hospital-adapted strains.

We identified outbreak clusters using cgMLST with ≤15 alleles threshold, which is routinely applied by the National Reference Centre for Enterococci for genomic surveillance and outbreak detection of *E. faecium* isolates (12, 47), revealing four dominant clusters (clusters 1-4). A commonly used ≤20 allele threshold (23) has been shown to lack sufficient discriminatory power for *E. faecium*, leading to the clustering of epidemiologically unrelated isolates and reduced resolution of transmission links (48). Recent studies advocate stricter clustering thresholds of ≤3 alleles to enhance discriminative power (49, 50); however, this conservative cut-off was derived for short-lived, spatially restricted outbreaks and may be too stringent for prolonged transmission events such as those analyzed here, where epidemiologically and phylogenetically linked cases naturally accumulate polymorphisms over time (51). We therefore applied an intermediate threshold of ≤15 alleles, which provides a balanced trade-off between sensitivity (detecting prolonged transmission events) and specificity (avoiding artificial clustering of unrelated lineages).

High-resolution genomic typing is increasingly recommended for hospital outbreak investigations (49). While cgMLST provides robust initial clustering, SKA enables refined discrimination, as demonstrated by Maechler *et al.* (48). We retrospectively applied SKA to ST117/CT71 isolates (cgMLST cluster 2), the main *vanB* peak driver. SKA resolved cgMLST cluster 2 into eight sub-clusters and 31 singletons, underscoring its high discriminatory power. This does not reflect an

increase in outbreak-related isolates, but rather a higher-resolution subdivision of previously
defined cgMLST clusters. Only one of eight SKA-defined clusters lacked likely epidemiological
connections (either indicative of potential transmission or isolates originating from the same
patient). The treating specialties of patients in cgMLST cluster 2 were consistent with previous
studies identifying visceral surgery as a risk factor for nosocomial VRE infections (52), and internal
medicine as having the highest incidence of VRE BSIs across six German university hospitals (33).
Analysis of longitudinal patient-movement data identified epidemiological links involving 29 of 47
patients whose isolates had been classified as SKA singletons. These epidemiological
connections, based on shared ward exposures, would have been difficult to detect manually due to
repeated admissions and intra-hospital transfers over extended periods. Notably, isolates classified
as SKA singletons exhibited significantly longer median intervals between linked BSI cases
compared to isolates within SKA-defined clusters, suggesting that the 7-SNP SKA cutoff may be
overly stringent for retrospective population studies involving prolonged transmission intervals. In
contrast, the ≤15 allele cgMLST threshold may overestimate relatedness, potentially clustering
genetically distinct isolates and generating false positives. Consequently, a tiered approach
integrating high-resolution methods (such as SKA), cgMLST clustering, and detailed
epidemiological analyses is necessary to balance sensitivity and specificity when investigating
potential transmission events. While our findings align with the two-step genomic analysis pipeline
proposed by Higgs *et al.* for investigating suspected VRE transmissions in real-time (49), our
results highlight the importance of calibrating thresholds to the specific surveillance context.

Several limitations of this study should be acknowledged. Due to its retrospective design,
comprehensive assessment of epidemiological links was not possible, particularly with regard to
the intestinal colonization status of patients. As a result, we could not determine the number of
nosocomially acquired isolates. Furthermore, detailed patient-movement data had to be extracted
manually from the hospital information system; to keep the effort within realistic limits, we retrieved
these data only for the largest cgMLST cluster (cluster 2), as it was most relevant to the *vanB*
peak. Other infection sites such as urinary tract infections, together with colonization sources (e.g.,
fecal isolates) and environmental reservoirs, on which VRE can persist for extended periods (53),
may have contributed to transmission but could not be systematically investigated in this
retrospective study. Recent evidence indicates that environmental reservoirs can account for
approximately one-third of potential VRE transmission events, with frequent detection on high-
contact sites such as patient chairs and surrounding surfaces (54). Other studies have shown that
VRE subtypes shared by multiple patients are often linked to contamination of communal
bathrooms and medical devices, underscoring the role of the inanimate environment in sustaining
transmission chains (55). Moreover, a recent comprehensive investigation from a Danish hospital
has shown that nearly all epidemiological links for *E. faecium* within the hospital can be detected
when isolates from all potential sources are analyzed (56). The study was conducted at a single
tertiary care center, which may limit the generalizability of the findings to other healthcare settings.

In addition, isolate availability varied across study years, particularly in 2019 and 2021, potentially
affecting the robustness of the population analysis during these periods.

Despite these limitations, our study demonstrates complex shifts in clonal lineages of *E. faecium*
and *van* genotypes at Hannover Medical School. The *vanB* peak observed in 2019 most likely
reflected a shift in the overall population structure of *E. faecium*. This shift was evident in the BSI
isolates analyzed here, which displayed an oligoclonal pattern dominated by ST117/CT71, along
with other *vanB*-positive clonal lineages, such as ST117/CT36 and ST117/CT1917. Of note, we
identified clusters of *van*-negative lineages (ST117/CT929 and ST117/CT2505). Such clusters of
van-negative *E. faecium* may be perceived as less concerning by clinicians due to available
treatment options, but they have to be addressed by IPC measures similar to those applied for
VRE. In genomic outbreak analysis, SKA and cgMLST provide complementary strengths, but their
limitations require careful consideration, as their outcomes have direct implications for outbreak
detection, reporting, and management. Adopting an integrated approach combining both methods
will enhance genomic surveillance and provide valuable insights to guide targeted infection control
strategies.

Data availability

All raw sequencing reads generated in this study have been deposited in the European Nucleotide
Archive (ENA) under the project accession number PRJEB91895. Raw data related to the
investigation of epidemiological links and additional metadata for the whole-genome sequences
cannot be shared publicly, as these data contain confidential patient information protected by the
German Data Privacy Act, as well as by the ethics committee and the data protection
commissioner of Hannover Medical School. Patient-related data, such as ward of admission, age,
sex, underlying disease, or length of stay, are considered indirect identifiers and could enable re-
identification of patients. To protect patient confidentiality and participants' privacy, only
anonymized and aggregated data can be made available. Researchers who meet the criteria for
access to confidential data may request anonymized data by contacting the data protection
commissioner of Hannover Medical School (datenschutz@mh-hannover.de) and the corresponding
author (knegendorf.leonard@mh-hannover.de). Data sharing is subject to approval by the ethics
committee and the data protection commissioner.

Acknowledgements

We thank the healthcare personnel on the wards for obtaining the patient samples, as well as the
technical staff of the Institute for Medical Microbiology and Hospital Epidemiology for isolating the
clinical strains and maintaining the strain collection. We thank Carola Fleige, Christine Bornstädt

and the staff at MF2-Genome Sequencing and Genomic Epidemiology Core of the Robert Koch
Institute for excellent technical assistance. We also thank PD Dr. Marius Vital for critically
discussing the scope of the study.

This research received no specific grant from any funding agency in the public, commercial, or not-
for-profit sectors.

References

1. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance.
Nat Rev Microbiol 10:266–278. https://doi.org/10.1038/nrmicro2761.

2. Scharloo F, Cogliati Dezza F, López-Hernández I, Martínez Pérez-Crespo PM, Goikoetxea
Aguirre AJ, Pérez-Rodríguez MT, Fernandez-Suarez J, León Jiménez E, Morán Rodríguez
MÁ, Fernández-Natal I, Reguera Iglesias JM, Natera Kindelán C, Fariñas Álvares MC, Boix-
Palop L, Lopez-Cortes LE, Rodríguez-Baño J, PROBAC/GEIRAS-SEIMC/SAMICEI group,
Jover-Sáenz A, Sánchez-Calvo JM, Gea-Lázaro I, Bahamonde Carrasco A, Vinuesa García
D, Del Arco Jiménez A, Smithson Amat A, Sánchez Porto A, Pérez Camacho I, Cuquet
Pedragosa J, Merino De Lucas E, Becerril Carral B, Martín Aspas A, Reche I. 2024. Clinical
characteristics, predisposing factors and outcomes for Enterococcus faecalis versus
Enterococcus faecium bloodstream infections: a prospective multicentre cohort study. Eur J
Clin Microbiol Infect Dis 43:2011–2022. https://doi.org/10.1007/s10096-024-04917-5.

3. Lebreton F, Van Schaik W, Manson McGuire A, Godfrey P, Griggs A, Mazumdar V, Corander
J, Cheng L, Saif S, Young S, Zeng Q, Wortman J, Birren B, Willems RJL, Earl AM, Gilmore
MS. 2013. Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal
and Commensal Strains. mBio 4:e00534-13. https://doi.org/10.1128/mBio.00534-13.

4. Belloso Daza MV, Cortimiglia C, Bassi D, Cocconcelli PS. 2021. Genome-based studies
indicate that the Enterococcus faecium Clade B strains belong to Enterococcus lactis species
and lack of the hospital infection associated markers. Int J Syst Evol Microbiol 71.
https://doi.org/10.1099/ijsem.0.004948.

5. Ocejo M, Mugica M, Oporto B, Lavín JL, Hurtado A. 2024. Whole-genome long-read
sequencing to unveil *Enterococcus* antimicrobial resistance in dairy cattle farms exposed a
widespread occurrence of *Enterococcus lactis*. Microbiol Spectr 12:e03672-23.
https://doi.org/10.1128/spectrum.03672-23.

6. Arthur M, Courvalin P. 1993. Genetics and mechanisms of glycopeptide resistance in
enterococci. Antimicrob Agents Chemother 37:1563–1571.
https://doi.org/10.1128/AAC.37.8.1563.

7. Cetinkaya Y, Falk P, Mayhall CG. 2000. Vancomycin-Resistant Enterococci. Clin Microbiol
Rev 13:686–707. https://doi.org/10.1128/CMR.13.4.686.

8. Brinkwirth S, Martins S, Ayobami O, Feig M, Noll I, Zacher B, Eckmanns T, Werner G, Willrich
N, Haller S. 2022. Germany's Burden of Disease of Bloodstream Infections Due to
Vancomycin-Resistant Enterococcus faecium between 2015–2020. Microorganisms 10:2273.
https://doi.org/10.3390/microorganisms10112273.

9. Vehreschild MJGT, Haverkamp M, Biehl LM, Lemmen S, Fätkenheuer G. 2019. Vancomycin-
resistant enterococci (VRE): a reason to isolate? Infection 47:7–11.
https://doi.org/10.1007/s15010-018-1202-9.

10. Jünemann S, Sedlazeck FJ, Prior K, Albersmeier A, John U, Kalinowski J, Mellmann A,
Goesmann A, Von Haeseler A, Stoye J, Harmsen D. 2013. Updating benchtop sequencing
performance comparison. Nat Biotechnol 31:294–296. https://doi.org/10.1038/nbt.2522.

11. Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK, Becker K, Borgmann S,
Diefenbach A, Hamprecht A, Hogardt M, Wichelhaus T, Kemp V, Huebner N-O, Kaasch A,
Geginat G, Kohnen W, Menzer A, Krause T, Miethke T, Pranada F, Radojn F, Tobisch S,
Jansen V, Regnath T, Bührlen U, Schneider-Brachert W, Schwarz R, Luemen M, Skov R,
Thuermer A, Baum HV, Weig M, Uwe G, Zabel L, Wulffen HV, Döring S. 2020. Thirty years of
VRE in Germany – "expect the unexpected": The view from the National Reference Centre for
Staphylococci and Enterococci. Drug Resist Updat 53:100732.
https://doi.org/10.1016/j.drup.2020.100732.

12. Bender JK, Hermes J, Zabel LT, Haller S, Mürter N, Blank H-P, Werner G, Hüttner I,
Eckmanns T. 2022. Controlling an Unprecedented Outbreak with Vancomycin-Resistant
Enterococcus faecium in Germany, October 2015 to November 2019. Microorganisms
10:1603. https://doi.org/10.3390/microorganisms10081603.

13. Chanumolu SK, Albahrani M, Otu HH. 2019. FQStat: a parallel architecture for very high-
speed assessment of sequencing quality metrics. BMC Bioinformatics 20:424.
https://doi.org/10.1186/s12859-019-3015-y.

14. Deneke C, Brendebach H, Uelze L, Borowiak M, Malorny B, Tausch SH. 2021. Species-
Specific Quality Control, Assembly and Contamination Detection in Microbial Isolate
Sequences with AQUAMIS. Genes 12:644. https://doi.org/10.3390/genes12050644.

15. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko
SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA,
Pevzner PA. 2012. SPAdes: A New Genome Assembly Algorithm and Its Applications to
Single-Cell Sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.

16. Roer L, Kaya H, Tedim AP, Novais C, Coque TM, Aarestrup FM, Peixe L, Hasman H,
Hammerum AM, Freitas AR, On behalf of the ESCMID Study Group for Epidemiological
Markers (ESGEM). 2024. VirulenceFinder for *Enterococcus faecium* and *Enterococcus*
lactis: an enhanced database for detection of putative virulence markers by using whole-
genome sequencing data. Microbiol Spectr 12:e03724-23.
https://doi.org/10.1128/spectrum.03724-23.

17. Hendrickx APA, Van Luit-Asbroek M, Schapendonk CME, Van Wamel WJB, Braat JC,
Wijnands LM, Bonten MJM, Willems RJL. 2009. SgrA, a Nidogen-Binding LPXTG Surface
Adhesin Implicated in Biofilm Formation, and EcbA, a Collagen Binding MSCRAMM, Are Two
Novel Adhesins of Hospital-Acquired *Enterococcus faecium*. Infect Immun 77:5097–5106.
https://doi.org/10.1128/IAI.00275-09.

18. Guzmán Prieto AM, Urbanus RT, Zhang X, Bierschenk D, Koekman CA, Van Luit-Asbroek M,
Ouwerkerk JP, Pape M, Paganelli FL, Wobser D, Huebner J, Hendrickx APA, Bonten MJM,
Willems RJL, Van Schaik W. 2015. The N-terminal domain of the thermo-regulated surface
protein PrpA of Enterococcus faecium binds to fibrinogen, fibronectin and platelets. Sci Rep
5:18255. https://doi.org/10.1038/srep18255.

19. Sillanpää J, Nallapareddy SR, Prakash VP, Qin X, Höök M, Weinstock GM, Murray BE. 2008.
Identification and phenotypic characterization of a second collagen adhesin, Scm, and
genome-based identification and analysis of 13 other predicted MSCRAMMs, including four
distinct pilus loci, in Enterococcus faecium. Microbiology 154:3199–3211.
https://doi.org/10.1099/mic.0.2008/017319-0.

20. Vankerckhoven V, Van Autgaerden T, Vael C, Lammens C, Chapelle S, Rossi R, Jabes D,
Goossens H. 2004. Development of a Multiplex PCR for the Detection of *asa1*, *gelE*, *cylA*,
esp, and *hyl* Genes in Enterococci and Survey for Virulence Determinants among European
Hospital Isolates of *Enterococcus faecium*. J Clin Microbiol 42:4473–4479.
https://doi.org/10.1128/JCM.42.10.4473-4479.2004.

21. Wagner TM, Janice J, Paganelli FL, Willems RJ, Askarian F, Pedersen T, Top J, De Haas C,
Van Strijp JA, Johannessen M, Hegstad K. 2018. *Enterococcus faecium* TIR-Domain Genes
Are Part of a Gene Cluster Which Promotes Bacterial Survival in Blood. Int J Microbiol
2018:1–17. https://doi.org/10.1155/2018/1435820.

22.   Rubin IMC, Karstensen KT, Lindegaard M, Hegstad K, Freitas AR, Hammerum AM, Roer L.
2025. Virulence signature of the endemic vancomycin-resistant *Enterococcus faecium* clones
in Denmark, 2015-2023. Microbiol Spectr 13:e01289-25.
https://doi.org/10.1128/spectrum.01289-25.

23.   De Been M, Pinholt M, Top J, Bletz S, Mellmann A, Van Schaik W, Brouwer E, Rogers M,
Kraat Y, Bonten M, Corander J, Westh H, Harmsen D, Willems RJL. 2015. Core Genome
Multilocus Sequence Typing Scheme for High-Resolution Typing of Enterococcus faecium. J
Clin Microbiol 53:3788–3797. https://doi.org/10.1128/JCM.01946-15.

24.   Harris SR. 2018. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology.
453142. bioRxiv https://doi.org/10.1101/453142.

25.   Gastmeier P, Schroder C, Behnke M, Meyer E, Geffers C. 2014. Dramatic increase in
vancomycin-resistant enterococci in Germany. J Antimicrob Chemother 69:1660–1664.
https://doi.org/10.1093/jac/dku035.

26.   Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. 2018.
Continuous increase of vancomycin resistance in enterococci causing nosocomial infections
in Germany – 10 years of surveillance. Antimicrob Resist Infect Control 7:54.
https://doi.org/10.1186/s13756-018-0353-x.

27.   Xanthopoulou K, Peter S, Tobys D, Behnke M, Dinkelacker AG, Eisenbeis S, Falgenhauer J,
Falgenhauer L, Fritzenwanker M, Gölz H, Häcker G, Higgins PG, Imirzalioglu C, Käding N,
Kern WV, Kramme E, Kola A, Mischnik A, Rieg S, Rohde AM, Rupp J, Tacconelli E,
Vehreschild MJGT, Walker SV, Gastmeier P, Seifert H, the DZIF R-Net Study Group, Bader
B, Foschi F, Gillis M, Hennelly C, Hoffmann N, Hölzl F, Lengler A, Lenke D, Diaz LAP, Peyerl-
Hoffmann G, Pilarski G, Proske S, Schmiedel J, Spitznagel H, Stelzer Y, Thoma N, Trauth J,
Vavra M, Weber A, Wille J, Bader B, Foschi F, Gillis M, Hennelly C, Hoffmann N, Hölzl F,
Lengler A, Lenke D, Diaz LAP, Peyerl-Hoffmann G, Pilarski G, Proske S, Schmiedel J,
Spitznagel H, Stelzer Y, Thoma N, Trauth J, Vavra M, Weber A, Wille J. 2020. Vancomycin-
resistant Enterococcus faecium colonizing patients on hospital admission in Germany:
prevalence and molecular epidemiology. J Antimicrob Chemother 75:2743–2751.
https://doi.org/10.1093/jac/dkaa271.

28.   Weber A, Maechler F, Schwab F, Gastmeier P, Kola A. 2020. Increase of vancomycin-
resistant Enterococcus faecium strain type ST117 CT71 at Charité - Universitätsmedizin
Berlin, 2008 to 2018. Antimicrob Resist Infect Control 9:109. https://doi.org/10.1186/s13756-
020-00754-1.

29.   Rhine-Main VREfm study group, Falgenhauer L, Fritzenwanker M, Imirzalioglu C, Steul K,
Scherer M, Heudorf U, Chakraborty T. 2019. Near-ubiquitous presence of a vancomycin-
resistant Enterococcus faecium ST117/CT71/vanB –clone in the Rhine-Main metropolitan
area of Germany. Antimicrob Resist Infect Control 8:128. https://doi.org/10.1186/s13756-019-
0573-8.

30.   Cimen C, Berends MS, Bathoorn E, Lokate M, Voss A, Friedrich AW, Glasner C, Hamprecht
A. 2023. Vancomycin-resistant enterococci (VRE) in hospital settings across European
borders: a scoping review comparing the epidemiology in the Netherlands and Germany.
Antimicrob Resist Infect Control 12:78. https://doi.org/10.1186/s13756-023-01278-0.

31.   Permana B, Harris PNA, Runnegar N, Lindsay M, Henderson BC, Playford EG, Paterson DL,
Beatson SA, Forde BM. 2023. Using Genomics To Investigate an Outbreak of Vancomycin-
Resistant Enterococcus faecium ST78 at a Large Tertiary Hospital in Queensland. Microbiol
Spectr 11:e04204-22. https://doi.org/10.1128/spectrum.04204-22.

32.   Hammerum AM, Karstensen KT, Roer L, Kaya H, Lindegaard M, Porsbo LJ, Kjerulf A, Pinholt
M, Holzknecht BJ, Worning P, Nielsen KL, Hansen SGK, Clausen M, Søndergaard TS, Dzajic
E, Østergaard C, Wang M, Koch K, Hasman H. 2024. Surveillance of vancomycin-resistant
enterococci reveals shift in dominating clusters from vanA to vanB Enterococcus faecium
clusters, Denmark, 2015 to 2022. Eurosurveillance 29. https://doi.org/10.2807/1560-
7917.ES.2024.29.23.2300633.

33. Hornuss D, Göpel S, Walker SV, Tobys D, Häcker G, Seifert H, Higgins PG, Xanthopoulou K,
Gladstone BP, Cattaneo C, Mischnik A, Rohde AM, Imirzalioglu C, Trauth J, Fritzenwanker M,
Falgenhauer J, Gastmeier P, Behnke M, Kramme E, Käding N, Rupp J, Peter S, Schmauder
K, Eisenbeis S, Kern WV, Tacconelli E, Rieg S, DZIF R.-N. E. T. Study Group, Peña Diaz LA,
Pilarski G, Thoma N, Peyerl-Hoffmann G, Gölz H, Joost I, Mathé P, Gillis M, Vehreschild M,
Wille J, Steffens B, Blum Y, Kleipass M, Lenke D, Herold S, Schmiedel J, Lengler A, Buhl M,
Hölzl F, Dinkelacker A. 2024. Epidemiological trends and susceptibility patterns of
bloodstream infections caused by Enterococcus spp. in six German university hospitals: a
prospectively evaluated multicentre cohort study from 2016 to 2020 of the R-Net study group.
Infection 52:1995–2004. https://doi.org/10.1007/s15010-024-02249-2.

34. Ayobami O, Willrich N, Reuss A, Eckmanns T, Markwart R. 2020. The ongoing challenge of
vancomycin-resistant *Enterococcus faecium* and *Enterococcus faecalis* in Europe: an
epidemiological analysis of bloodstream infections. Emerg Microbes Infect 9:1180–1193.
https://doi.org/10.1080/22221751.2020.1769500.

35. Fischer MA, Bender JK, Kriebel N, Weber RE, Wohlfarth E, Maechler F, Noll I, Abu Sin M,
Werner G. 2023. Eigenschaften, Häufigkeit und Verbreitung von Vancomycin-resistenten
Enterokokken in Deutschland – Update. Epidemiol Bull 28:3–17.
https://doi.org/10.25646/11609.

36. Mills EG, Hewlett K, Smith AB, Griffith MP, Pless L, Sundermann AJ, Harrison LH, Zackular
JP, Van Tyne D. 2025. Bacteriocin production facilitates nosocomial emergence of
vancomycin-resistant Enterococcus faecium. Nat Microbiol 10:871–881.
https://doi.org/10.1038/s41564-025-01958-0.

37. Lee T, Pang S, Daley DA, Pearson JC, Abraham S, Coombs GW. 2022. The changing
molecular epidemiology of Enterococcus faecium harbouring the van operon at a teaching
hospital in Western Australia: A fifteen-year retrospective study. Int J Med Microbiol
312:151546. https://doi.org/10.1016/j.ijmm.2021.151546.

38. Van Tyne D, Gilmore MS. 2014. Friend Turned Foe: Evolution of Enterococcal Virulence and
Antibiotic Resistance. Annu Rev Microbiol 68:337–356. https://doi.org/10.1146/annurev-
micro-091213-113003.

39. Brinkwirth S, Feig M, Noll I, Eckmanns T, Dörre A, Haller S, Willrich N. 2025. Changing
dynamics of bloodstream infections due to methicillin-resistant Staphylococcus aureus and
vancomycin-resistant Enterococcus faecium in Germany, 2017–2023: a continued burden of
disease approach. Antimicrob Resist Infect Control 14:4. https://doi.org/10.1186/s13756-025-
01522-9.

40. Genath A, Hackmann C, Denkel L, Weber A, Maechler F, Kola A, Schwarz S, Gastmeier P,
Leistner R. 2024. The genetic relationship between human and pet isolates: a core genome
multilocus sequence analysis of multidrug-resistant bacteria. Antimicrob Resist Infect Control
13:107. https://doi.org/10.1186/s13756-024-01457-7.

41. Kampmeier S, Tönnies H, Correa-Martinez CL, Mellmann A, Schwierzeck V. 2020. A
nosocomial cluster of vancomycin resistant enterococci among COVID-19 patients in an
intensive care unit. Antimicrob Resist Infect Control 9:154. https://doi.org/10.1186/s13756-
020-00820-8.

42. Rath A, Kieninger B, Caplunik-Pratsch A, Fritsch J, Mirzaliyeva N, Holzmann T, Bender JK,
Werner G, Schneider-Brachert W. 2024. Concerning emergence of a new vancomycin-
resistant Enterococcus faecium strain ST1299/CT1903/vanA at a tertiary university centre in
South Germany. J Hosp Infect 143:25–32. https://doi.org/10.1016/j.jhin.2023.10.008.

43. Kavanagh NL, Kinnevey PM, Egan SA, McManus BA, O'Connell B, Brennan GI, Coleman
DC. 2024. Protracted transmission and persistence of ST80 vancomycin-resistant
Enterococcus faecium clonal complex types CT2933, CT2932 and CT1916 in a large Irish
hospital: a 39-month whole-genome sequencing study. J Hosp Infect 151:11–20.
https://doi.org/10.1016/j.jhin.2024.06.002.

44. Hansen SGK, Roer L, Karstensen KT, Hoegh SV, Hansen F, Klein K, Rosenvinge FS, Holm
A, Skov MN, Hammerum AM, Hasman H. 2023. Vancomycin-sensitive Enterococcus faecium
bacteraemia – hospital transmission and mortality in a Danish University Hospital. J Med
Microbiol 72. https://doi.org/10.1099/jmm.0.001731.

45. Lehmkuhl J, Schneider JS, Werth KLV, Scherff N, Mellmann A, Kampmeier S. 2024. Role of
membrane vesicles in the transmission of vancomycin resistance in Enterococcus faecium.
Sci Rep 14:1895. https://doi.org/10.1038/s41598-024-52310-1.

46. Sobkowiak A, Scherff N, Van Almsick V, Schuler F, Brix TJ, Mellmann A, Schwierzeck V.
2025. Characterization of vanA-harboring plasmids supports differentiation of outbreak-
related and sporadic vancomycin-resistant Enterococcus faecium isolates in a tertiary care
hospital. BMC Microbiol 25:337. https://doi.org/10.1186/s12866-025-04058-5.

47. Trautmannsberger I, Kolberg L, Meyer-Buehn M, Huebner J, Werner G, Weber R, Heselich V,
Schroepf S, Muench H-G, Von Both U. 2022. Epidemiological and genetic characteristics of
vancomycin-resistant Enterococcus faecium isolates in a University Children's Hospital in
Germany: 2019 to 2020. Antimicrob Resist Infect Control 11:48.
https://doi.org/10.1186/s13756-022-01081-3.

48. Maechler F, Weber A, Schwengers O, Schwab F, Denkel L, Behnke M, Gastmeier P, Kola A.
2023. Split k-mer analysis compared to cgMLST and SNP-based core genome analysis for
detecting transmission of vancomycin-resistant enterococci: results from routine outbreak
analyses across different hospitals and hospitals networks in Berlin, Germany. Microb
Genomics 9. https://doi.org/10.1099/mgen.0.000937.

49. Higgs C, Sherry NL, Seemann T, Horan K, Walpola H, Kinsella P, Bond K, Williamson DA,
Marshall C, Kwong JC, Grayson ML, Stinear TP, Gorrie CL, Howden BP. 2022. Optimising
genomic approaches for identifying vancomycin-resistant Enterococcus faecium transmission
in healthcare settings. Nat Commun 13:509. https://doi.org/10.1038/s41467-022-28156-4.

50. Caplunik-Pratsch A, Kieninger B, Donauer VA, Brauer JM, Meier VMK, Seisenberger C, Rath
A, Loibl D, Eichner A, Fritsch J, Schneider-Brachert W. 2024. Introduction and spread of
vancomycin-resistant Enterococcus faecium (VREfm) at a German tertiary care medical
center from 2004 until 2010: a retrospective whole-genome sequencing (WGS) study of the
molecular epidemiology of VREfm. Antimicrob Resist Infect Control 13:20.
https://doi.org/10.1186/s13756-024-01379-4.

51. Bayjanov JR, Baan J, Rogers MRC, Troelstra A, Willems RJL, Van Schaik W. 2019.
Enterococcus faecium genome dynamics during long-term asymptomatic patient gut
colonization. Microb Genomics 5. https://doi.org/10.1099/mgen.0.000277.

52. Jochim-Vukosavic A, Schwab F, Knegendorf L, Schlüter D, Bange F-C, Ebadi E, Baier C.
2024. Epidemiology and infection control of vancomycin-resistant enterococci at a German
university hospital: A three-year retrospective cohort study. PLOS ONE 19:e0297866.
https://doi.org/10.1371/journal.pone.0297866.

53. Wagenvoort JHT, De Brauwer EIGB, Penders RJR, Willems RJ, Top J, Bonten MJ. 2011.
Environmental survival of vancomycin-resistant Enterococcus faecium. J Hosp Infect 77:282–
283. https://doi.org/10.1016/j.jhin.2010.11.008.

54. Macesic N, Cottingham H, Wisniewski JA, Blakeway LV, Theegala R, Pragastis K,
Stewardson A, Bass P, Gritt M, Spilsbury S, Del Rosario-Kelly D, Dennison A, Spelman DW,
Jenney AWJ, Peleg AY. 2025. Hospital Enterococcus faecium demonstrates distinct
environmental and patient reservoirs: a genomic point prevalence survey. Infect Control Hosp
Epidemiol 46:540–543. https://doi.org/10.1017/ice.2025.27.

55. Gouliouris T, Coll F, Ludden C, Blane B, Raven KE, Naydenova P, Crawley C, Török ME,
Enoch DA, Brown NM, Harrison EM, Parkhill J, Peacock SJ. 2020. Quantifying acquisition
and transmission of Enterococcus faecium using genomic surveillance. Nat Microbiol 6:103–
111. https://doi.org/10.1038/s41564-020-00806-7.

56.   Hertz FB, Nielsen KL, Strunin D, Erdmann J, Jørgensen ML, Bendixen T, Srinathan R, Marvig
719   RL, Rasmussen SC, Rasmussen AN, Jensen CS, Knudsen JD, Häussler S. 2025. Estimating
720   the potential economic and health impact of integrated genomic surveillance in a hospital
721   setting. Clin Microbiol Infect S1198743X25004720. https://doi.org/10.1016/j.cmi.2025.09.021.

Figures

Figure 1: Phenotypic background of the VanB peak at Hannover Medical School from (2013 to 2024_1). The solid (VanB) and dashed (VanA) lines show the number of VRE patients per half-year from any specimen type (routine clinical or screening) across all hospital departments. The light-blue area indicates the total number of patients treated hospital-wide (cases) per half-year in the same interval.

Figure 2: Overview of the isolates analyzed in this study. (A) Flowchart depicting the selection process of *E. faecium* isolates from BSIs. Exclusions due to unavailability, quality control issues, and duplicate cases are indicated, along with the stratification of isolates into *vanA*-, *vanB*-, and *van*-negative genotypes. **(B)** Proportion of isolates included in the final analysis relative to the total number of isolates meeting the inclusion criteria separated by year.

Figure 3: Characterization and temporal distribution of invasive VRE isolates at Hannover Medical School from 2017_2 to 2022_1. (A) Number of isolates per half-year, categorized by ST and CT. **(B)** Proportion of isolates assigned to each ST/CT over time. **(C)** Proportion of isolates with *vanA*, *vanB*, and *van*-negative genotypes over time. **(D)** Total number of isolates for each ST/CT, stratified by *vanA*, *vanB*, and *van*-negative genotypes.

Figure 4: MST of invasive VRE isolates collected from 2017_2 to 2022_1 at Hannover Medical School. The MST was inferred based on cgMLST applying the "pairwise ignore missing values" option. **(A)** Distribution of STs and CTs. Clusters (shown as dark gray shaded areas and labeled with black cluster numbers) were defined using a pairwise allelic difference threshold of ≤15 alleles and are numbered by ascending size. **(B)** Distribution of *van* genotypes: *vanA* (gray), *vanB* (black), *van*-negative (white).

Figure 5: Hierarchical classification of *E. faecium* isolates based on different typing methods. CgMLST clusters were defined using a pairwise allelic difference threshold of ≤15 alleles. SKA clusters were defined by a 7-SNP threshold. Connecting lines indicate how individual isolates are assigned across typing methods. Node size corresponds to the number of isolates per category, and node labels indicate ST, CT, or cluster number, as designated by the column-specific headers above each group of nodes.

Figure 6: Identification of epidemiological links in SKA-defined outbreak clusters. (A) Sankey diagram illustrating how cgMLST cluster 2 partitions into distinct SKA clusters and singletons. **(B)** Visualization of epidemiological connections within SKA clusters. The colors of the circles represent the year of isolation. Lines indicate patient contact categories, based on defined ward-level overlaps.

Resistance phenotype *E. faecium* VRE

A

414 *E. faecium* isolates from blood cultures with AST data

68 isolates not stored
2 isolates used for testing of sequencing platform

344 isolates sequenced

11 isolates excluded due to inadequate QC parameters

333 isolates included in analysis

van negative N=238

vanA N=19

vanB N=76

32 isolates excluded (same patient and CT)

2 isolates excluded (same patient and CT)

10 isolates excluded (same patient and CT)

duplicate exclusion for population analysis

van negative adjusted for duplicates N=206

vanA adjusted for duplicates N=17

vanB adjusted for duplicates N=66

B

Number of isolates

100%   81.3%   75.4%   86.0%   74.8%   86.0%

2017   2018   2019   2020   2021   2022

Year

Included in analysis
No
Yes